why choose us

First received: March 06, 2023

Clinical Trial: A Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation-Positive Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-label Study of BDTX-4933 in Patients With BRAF and Other Select RAS/MAPK Mutation-Positive Neoplasms

Brief Summary: BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and multiple expansion cohort study designed to evaluate the safety and antitumor activity of BDTX-4933.The study population comprises adults with recurrent advanced/metastatic cancers harboring BRAF (Class I, II, and III), KRAS (other than G12C such as G12D, G12V), or NRAS mutations including non-small cell lung cancer (NSCLC), melanoma, histiocytic neoplasms, thyroid cancer, colorectal cancer, and other solid tumor cancers with or…

Read more